DX
Disease Management, Mechanisms, and Treatment (Poster)
Thursday, May 29, 2014: 7:00 PM-8:30 PM
Trinity Exhibit Hall
Good Treatment Adherence Is Maintained in MS Patients Using RebiSmart: Assessment of the MEASURE Primary Endpoint
Alan Gillett, PhD, EMD Serono;
Virginia Devonshire, MD, University of British Columbia;
Anthony Feinstein, MPhil, PhD, FRCP, University of Toronto, Sunnybrook Health Sciences Centre;
Patrick Moriarty, PhD, EMD Serono
Vitamin D Deficiency As an Early Predictor of Long-Term Disease Activity in Patients Starting Interferon Beta-1b at Clinically Isolated Syndrome
Alberto Ascherio, MD, Harvard School of Public Health;
Kassandra Munger, ScD, Harvard School of Public Health;
Richard A White, MSc, University of British Columbia;
Karl Köchert, PhD, Bayer Pharma AG;
Kelly C Simon, ScD, Harvard School of Public Health;
Chris H Polman, MD, VU Medical Centre;
Mark S Freedman, MD, Ottawa Hospital Research Institute;
Hans-Peter Hartung, MD, Heinrich-Heine Universität;
David H Miller, MD, National Hospital for Neurology and Neurosurgery;
Xavier Montalbán, MD, Hospital Universitari Vall d’Hebron;
Gilles Edan, MD, CHU-Hôpital Pontchaillou;
Frederik Barkhof, MD, PhD, VU University Medical Center;
Dirk Pleimes, MD, Myelo Therapeutics GmbH;
Ernst W Radü, MD, University Hospital Basel;
Rupert Sandbrink, MD, Bayer Pharma AG;
Ludwig Kappos, MD, University Hospital Basel;
Christoph Pohl, MD, University Hospital of Bonn
Teriflunomide Selectively Impacts the Immune System and Does Not Impair Protective Responses: Preclinical and Clinical Data
Amit Bar-Or, MD, FRCPC, Montreal Neurological Institute and Hospital, McGill University;
Johanne Kaplan, PhD, Genzyme, a Sanofi Company;
Andrea Edling, PhD, Genzyme, a Sanofi Company;
Françoise Menguy-Vacheron, PhD, Sanofi;
Philippe Truffinet, MD, Genzyme, a Sanofi company;
Heinz Wiendl, MD, University of Münster
Alopecia Barbae after Longterm Natalizumab Therapy
Jill R Nelson, RN BScN MSCN, Fraser Health Multiple Sclerosis Clinic;
Anna Kazimirchik, RN MSCN, Fraser Health Multiple Sclerosis Clinic;
Sinead McGowan, B.Sci., Fraser Health Multiple Sclerosis Clinic;
Galina Vorobeychik, MD, FRCPS(C), CMSC, Fraser Health Multiple Sclerosis Clinic
Persistence, Adherence, and Quality of Life in Patients Treated with an Intramuscular Interferon Beta-1a Autoinjector in a Real-World Clinical Setting
Antonio Vasco Salgado, MD, Hospital Fernando Fonseca;
Raymond Hupperts, MD, Maastricht University, Maastricht, and Orbis Medical Center;
Sergio Slawka, MD, MPH, Biogen Idec Inc.;
Xiaojun You, PhD, Biogen Idec Inc.;
Bjorn Sperling, MD, Biogen Idec Inc.
Patient- and Physician-Reported Outcomes after Therapy Switch from Interferons or Glatiramer Acetate to Fingolimod
Bruce A.C. Cree, MD, PhD, MCR, University of California San Francisco Medical Center;
Keith R. Edwards, MD, FAAN, MS Center of Northeastern New York;
Kevin McCague, MA, Novartis Pharmaceuticals Corporation;
Luigi M. Barbato, MD, Novartis Pharmaceuticals Corporation
Effect of Bismuth Subsalicylate on Gastrointestinal Tolerability in Healthy Volunteers Receiving Delayed-Release Dimethyl Fumarate
Carlo Tornatore, MD, Georgetown University Hospital;
Jie Li, MD, Biogen Idec, Inc.;
Tina S Ma, PhD, PharmStats, Ltd.;
Javier Zambrano, MD, Biogen Idec, Inc.
Treatment-Naive RRMS Patients More Likely to be Disease Activity Free with Alemtuzumab Than Subcutaneous Interferon Beta-1a Across Patient Subgroups
Carolina Ionete, MD/PhD, University of Massachusetts Medical School;
Steven Galetta, MD, New York University Langone Medical Center;
Jeffrey Palmer, MS, Genzyme, a Sanofi company;
David H Margolin, MD, PhD, Genzyme, a Sanofi company
Safety and Efficacy of Teriflunomide in Patients with Relapsing Remitting MS (RRMS) in a Community Setting
Claudia Chaves, MD, Lahey Clinic;
Caitlin A Dionne, RN, BSN, MSCN, Lahey Clinic;
Rik Ganguly, BS, Lahey Clinic;
Ann Camac, MD, Lahey Clinic
Application of the Delphi Technique for Evaluation of the Tolerability Profile of Pegylated Interferon Beta-1a
Diego Centonze, MD, PhD, Policlinico Universitario Tor Vergata;
Chris Robertson, PharmD, Biogen Idec;
June Halper, MSN, ANP, FAAN, Multiple Sclerosis Center, New Jersey Medical School;
DeRen Huang, MD, PhD, Neurology and Neuroscience Associates;
Scott D Newsome, D.O., Johns Hopkins Hosptial;
Xiaojun You, PhD, Biogen Idec;
Leslie Leahy, PhD, Biogen Idec;
Bjorn Sperling, MD, Biogen Idec
Fingolimod Effect on Relapse Rate in Young Adult Patients with Multiple Sclerosis
Göril Karlsson, PhD, Novartis Pharma AG;
Dieter A Häring, PhD, Novartis Pharma AG;
Philipp von Rosenstiel, MD, Novartis Pharma AG;
Gordon Francis, MD, Novartis Pharmaceuticals Corporation;
Peter Chin, MD, Novartis Pharmaceuticals Corporation;
Norman Putzki, MD, Novartis Pharma AG
Teriflunomide Mechanism of Action: Linking Preclinical Evidence to Clinical Activity
Heinz Wiendl, MD, University of Münster;
Andrew R Pachner, MD, Dartmouth-Hitchcock Medical Center and Geisel School of Medicine at Dartmouth;
Johanne Kaplan, PhD, Genzyme, a Sanofi Company;
Françoise Menguy-Vacheron, PhD, Sanofi;
Philippe Truffinet, MD, Genzyme, a Sanofi company;
Amit Bar-Or, MD, FRCPC, Montreal Neurological Institute and Hospital, McGill University
Safety Profile of Delayed-Release Dimethyl Fumarate in Relapsing-Remitting MS: Long-Term Interim Results from the ENDORSE Extension Study
J. Theodore Phillips, MD, PhD, FAAN, Multiple Sclerosis Program, Baylor Institute for Immunology Research;
Robert J Fox, MD, FAAN, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic;
Krzysztof Selmaj, MD, PhD, Medical University of Lodz;
Ray Zhang, PhD, Biogen Idec, Inc.;
Mark Novas, MD, Biogen Idec, Inc.;
Marianne Sweetser, MD, PhD, Biogen Idec, Inc.;
Vissia Viglietta, MD, PhD, Biogen Idec, Inc.;
Ralf Gold, MD, St Josef Hospital, Ruhr University
A Delphi Panel to Address Management of Gastrointestinal Side Effects Observed with Use of Delayed-Release Dimethyl Fumarate
J. Theodore Phillips, MD, PhD, FAAN, Multiple Sclerosis Program, Baylor Institute for Immunology Research;
April Erwin, MD, The NeuroMedical Center Clinic;
Stephanie Agrella, RN, MSN, APRN, ANP-BC, MSCN, Multiple Sclerosis Clinic of Central Texas;
Marcelo Kremenchutzky, MD, FRCPC, FAAN, Multiple Sclerosis Clinic & Research Centre;
John Kramer, PA-C, Wheaton Franciscan Regional MS Center;
Robert J Fox, MD, FAAN, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic
Lymphocyte Count Reductions in Relapsing-Remitting MS Patients Treated with Delayed-Release Dimethyl Fumarate: Integrated Analysis of the Placebo-Controlled Studies
J. Theodore Phillips, MD, PhD, FAAN, Multiple Sclerosis Program, Baylor Institute for Immunology Research;
Robert J Fox, MD, FAAN, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic;
Ralf Gold, MD, St Josef Hospital, Ruhr University;
Krzysztof Selmaj, MD, PhD, Medical University of Lodz;
Kartik Raghupathi, MS, Biogen Idec, Inc.;
Huixing Yuan, PhD, Biogen Idec, Inc.;
John O'Gorman, PhD, Biogen Idec, Inc.;
Mark Novas, MD, Biogen Idec, Inc.;
Vissia Viglietta, MD, PhD, Biogen Idec, Inc.;
Nuwan C Kurukulasuriya, PhD, Biogen Idec, Inc.
Management of Reported Side Effects of Patients Initiating Therapy on Dimethyl Fumarate
Jaspreet K. Abraham, RN, BSN, MSCS, UT Southwestern Medical Center;
Gina Remington, RN, BSN, MSCN, UT Southwestern Medical Center;
Victoria Stokes, RN, UT Southwestern Medical Center;
Yolanda T Rodriguez, BSN, RN, MSCS, UT Southwestern Medical Center;
Diana W. Logan, RN, FNP-C, BC, MSCN, UT Southwestern Medical Center;
Teresa Frohman, MPAS, PA-C, UT Southwestern Medical Center;
Elliot Frohman, MD, PhD, FAAN, UT Southwestern Medical Center
Oral Therapy Safety Compliance
Jeffrey B English, MD, Multiple Sclerosis Center of Atlanta;
Kaitlin E English, student, Multiple Sclerosis Center of Atlanta;
Katie Bailey, student, Multiple Sclerosis Center of Atlanta
Design and Baseline Characteristics of a Pilot Trial of Lithium for Progressive Multiple Sclerosis
John R Rinker II, MD, Birmingham VA Medical Center;
Beverly A Layton, RN, Birmingham VA Medical Center;
Victor Sung, MD, Birmingham VA Medical Center;
Anthony Nicholas, MD, Birmingham VA Medical Center;
William R Meador, MD, Birmingham VA Medical Center
Delayed-Release Dimethyl Fumarate As Add-on Therapy to Beta Interferon or Glatiramer Acetate in Relapsing-Remitting MS: Safety and Tolerability
Jonathan Calkwood, MD, Schapiro Center for Multiple Sclerosis, Minneapolis Clinic of Neurology;
Vissia Viglietta, MD, PhD, Biogen Idec, Inc.;
Timothy Vollmer, MD, University of Colorado School of Medicine, RMMSC at Anschutz;
Ray Zhang, PhD, Biogen Idec, Inc.;
Mark Novas, MD, Biogen Idec, Inc.;
Sarah I. Sheikh, MD, Biogen Idec Inc.;
Robert J Fox, MD, FAAN, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic
Treatment Effect on T1 Hypointense Lesions: Evaluation of Two Different Methodologies in RRMS Subjects from the GALA Study
Robert Zivadinov, MD, PhD, State University of New York at Buffalo;
Omar Khan, MD, Wayne State University;
Michael G. Dwyer, PhD, State University of New York at Buffalo;
Deepa P Ramasamy, MD, State University of New York at Buffalo;
Hadas Barkay, PhD, Teva Pharmaceuticals;
Abi Vainstein-Haras, MD, Teva Pharmaceuticals;
Joshua R Steinerman, MD, Teva Pharmaceuticals;
Volker Knappertz, MD, DMSc, Teva Pharmaceuticals
Pregnancy Outcomes in Partners of Male Study Participants Treated with Teriflunomide
Lily Jung Henson, MD, Swedish Medical Center;
Lynn Davenport, PhD, Sanofi;
Myriam Benamor, MD, Sanofi;
Andreas Czich, PhD, Sanofi;
Sandrine Turpault, PharmD, Sanofi
Cardiac-Related Infusion-Associated Reactions in Relapsing-Remitting Multiple Sclerosis Patients Treated with Alemtuzumab
Lise Casady, MSCN, ARNP-C, University of South Florida;
Cathy Meyer, RN, MSCN, Consultants in Neurology;
Stanley Krolczyk, DO, RPh, Genzyme, a Sanofi company;
Pedro Oyuela, MD, MPH, Genzyme, a Sanofi company;
Jeffrey Palmer, MS, Genzyme, a Sanofi company;
David H Margolin, MD, PhD, Genzyme, a Sanofi company
A Case of Mistaken Identity: Natalizumab, Dermatographia and Infusion Reaction
Marijean Buhse, PhD, NP-C, South Shore Neurologic;
Barbara Bumstead, NP-C, South Shore Neurologic;
Myassar Zarif, MD, South Shore Neurologic;
Lori Fafard, RN, South Shore Neurologic;
Mark Gudesblatt, MD, South Shore Neurologic Associates
A Rash of Rashes: Multiple Sclerosis, Natalizumab Therapy, Bullous Pemphigoid
Marijean Buhse, PhD, NP-C, South Shore Neurologic;
Barbara Bumstead, NP-C, South Shore Neurologic;
Myassar Zarif, MD, South Shore Neurologic;
Lori Fafard, RN, South Shore Neurologic;
Mark Gudesblatt, MD, South Shore Neurologic Associates
Early and Consistent Benefits of Interferon Beta-1a SC in Relapsing Multiple Sclerosis: Post Hoc Analysis of Prisms MRI Data
Mark Cascione, MD, South Tampa Multiple Sclerosis Center;
Carol Gaines, MD, EMD Serono, Inc.;
Juanzhi Fang, BMed, MS, EMD Serono, Inc.;
Fernando Dangond, MD, EMD Serono, Inc.;
Aaron Miller, MD, Icahn School of Medicine at Mount Sinai
Consistent Treatment Effect of Teriflunomide in Subgroups Based on Pre-Trial Therapy: Pooled Analyses of Temso and Tower
Mark S Freedman, MD, University of Ottawa and the Ottawa Hospital Research Institute;
Deborah Dukovic, MS, Sanofi;
Myriam Benamor, MD, Sanofi;
Philippe Truffinet, MD, Genzyme, a Sanofi company;
Ludwig Kappos, MD, University Hospital Basel
Consensus on Optimal Multiple Sclerosis Injectable Treatment Management to Improve Patient Adherence: The MS Delphi Project
Monique Booy, MANP, Amphia Hospital, MS centre;
Lisette Trommelen, MANP, MS-center Midden Brabant;
Astrid Slettenaar, MANP, MS-center Twente;
Leo Visser, MD, St Elisabeth Hospital;
Klaas Arts, MD, Winkler clinic, Pro Persona
Improved Estimation of Treatment Effects: Analysis of Time to Recurrent Relapse with Fingolimod or Ifnβ-1a Using Proportional Means Model
Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation;
Zahur Islam, PhD, Novartis Pharmaceuticals Corporation;
Peter Chin, MD, Novartis Pharmaceuticals Corporation;
Nadia Tenenbaum, MD, Novartis Pharmaceuticals Corporation;
Gary Cutter, PhD, University of Alabama
The Strive Study of Natalizumab in Patients with Early MS: Baseline Characteristics
Roumen Balabanov, MD, Rush University Multiple Sclerosis Center;
Jai Perumal, MD, Judith Jaffe Multiple Sclerosis Center;
Robert J Fox, MD, FAAN, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic;
Denise Campagnolo, MD, Biogen Idec Inc.;
Emese Dian, PhD, Biogen Idec Inc.;
Stefan Lanker, PhD, Biogen Idec Inc.;
Mary-Jean Fanelli, MD, MBA, Biogen Idec Inc.
Early Adopters of Tecfidera: Preliminary Characteristics and Patient-Reported Outcomes from the NARCOMS Registry
Stacey S Cofield, PhD, University of Alabama at Birmingham;
Tuula Tyry, PhD, St. Joseph’s Hospital and Medical Center;
Ruth Ann Marrie, MD, PhD, FRCPC, University of Manitoba;
Robert J Fox, MD, FAAN, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic;
John S Walsh, MD, Biogen Idec;
Gary Cutter, PhD, University of Alabama at Birmingham
Efficacy and Safety of Peginterferon Beta-1a in Relapsing-Remitting Multiple Sclerosis: 2-Year Data from the ADVANCE Study
Scott D Newsome, D.O., Johns Hopkins University;
Bernd C Kieseier, MD, Heinrich-Heine University;
Laura J Balcer, MD, New York University, Langone Medical Center;
Alexey Boyko, MD, Moscow MS Center at RSMU;
Jean Pelletier, MD, CHU Timone;
Shifang Liu, PhD, Biogen Idec Inc.;
Ying Zhu, PhD, Biogen Idec Inc.;
Ali Seddighzadeh, MD, Biogen Idec Inc.;
Serena Hung, MD, Biogen Idec Inc.;
Aaron Deykin, MD, Biogen Idec Inc.
Peginterferon Beta-1a May Improve Recovery Following Relapses in the ADVANCE Relapsing-Remitting Multiple Sclerosis Study
Scott D Newsome, D.O., Johns Hopkins University;
Thomas F Scott, MD, Drexel University College of Medicine;
Bernd C Kieseier, MD, Heinrich-Heine University;
Sarah I. Sheikh, MD, Biogen Idec Inc.;
Serena Hung, MD, Biogen Idec Inc.;
Xiaojun You, PhD, Biogen Idec Inc.;
Bjorn Sperling, MD, Biogen Idec Inc.
Autoinjector Ease-of-Use in Patients with MS Treated with Interferon Beta-1a Subcutaneously: Redefine Study Design
Sibyl Wray, MD, Hope Neurology Multiple Sclerosis Center;
Barry Singer, MD, Missouri Baptist Medical Center;
Juanzhi Fang, BMed, MS, EMD Serono, Inc.;
Ali Hassan, MD, EMD Serono, Inc.;
Fernando Dangond, MD, EMD Serono, Inc.
Changes in Immunological Biomarkers in Patients with Relapsing–Remitting Multiple Sclerosis Treated with Interferon Beta-1a
Silva Markovic-Plese, MD, University of North Carolina at Chapel Hill;
Yazhong Tao, PhD, University of North Carolina at Chapel Hill;
Xin Zhang, MD, University of North Carolina at Chapel Hill;
Bianca Weinstock-Guttman, MD, State University of New York at Buffalo;
Robert Zivadinov, MD, PhD, State University of New York at Buffalo, Buffalo Neuroimaging Analysis Center;
Brooke Hayward, SM, MBA, EMD Serono, Inc.;
Fernando Dangond, MD, EMD Serono, Inc.
Study Design of Transition: An Observational Study to Evaluate the Safety Profile of Fingolimod in Patients Switched from Natalizumab
Stanley Cohan, MD, Providence Multiple Sclerosis Center,;
Maria Trojano, MD, University of Bari;
Arijit Sinha, Ph.D, Novartis Healthcare Pvt Ltd.;
Moreshwar Patwardhan, M.Pharm, Novartis Healthcare Pvt Ltd.;
Davorka Tomic, MD, Novartis Pharma AG
A Phase II Double-Blind Placebo Cross-over Clinical in Secondary Progressive Multiple Sclerosis
Syed Haq, BSc MBBS PhD DIC MRCP(UK), Daval International Ltd;
Christopher E Moore, BSc, MBBS, PhD, FRCP, Queen Alexandra Hospital, Portsmouth, UK.;
Jeffery Vernes, BSc, School of Mathematics, Statistics and Actuarial Science;
Deirdre McIntosh, BA PhD, Daval International Ltd
Study Design of a Phase 3 Trial Evaluating Teriflunomide in Children and Adolescents with Relapsing Multiple Sclerosis
Tanuja Chitnis, MD, Massachusetts General Hospital for Children;
Brenda Banwell, MD, Children's Hospital of Philadelphia;
Douglas L Arnold, MD, McGill University;
Philippe Truffinet, MD, Genzyme, a Sanofi company;
Deborah Dukovic, MS, Sanofi;
Michael A Panzara, MD, Genzyme, a Sanofi company;
Ludwig Kappos, MD, University Hospital Basel
Weight and BMI Changes over 7 Years in CombiRx
Tarah Gustafson, BSN, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine;
Fred D. Lublin, MD, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine;
Jerry S Wolinsky, MD, The University of Texas Health Science Center at Houston Medical School;
Gary Cutter, PhD, University of Alabama at Birmingham;
Robin Conwit, MD, NIH;
Stacey S Cofield, PhD, University of Alabama at Birmingham
The Effect of Glatiramer Acetate Treatment on Mitochondrial Fission/Fusion in EAE
Vamshi Nimmagadda, M.B.B.S., University of Maryland School of Medicine;
Christopher T Bever Jr., M.D., M.B.A., VA Maryland Health Care System;
Rupal Jain, BA, University of Maryland School of Medicine;
Susan I Judge, Ph.D., VA Maryland Health Care System;
David Trisler, Ph.D., VA Maryland Health Care System;
Tapas K Makar, Ph.D., University of Maryland School of Medicine
